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We have engineered GPCR (G protein-coupled receptor) knock-out and high GAG-binding affinity
into CXCL12a to inhibit CXCL12a-induced cell migration. Compared to wtCXCL12, the mutant
CXCL12a (D8 L29K V39K) exhibited a 5.6-fold and a 2.2-fold affinity increase for heparin and hep-
aran sulfate, respectively. From NaCl-based heparin displacement chromatography we concluded
that more amino acid replacements would lead to altered GAG (glycosaminoglycan) ligand
specificity. GAG silencing by this mutant was shown in a murine seeding model of human cancer
cells, whereby a greatly reduced number of liver metastases was detected when the animals were
treated intravenously with 1 mg/kg CXCL12a (D8 L29K V39K) before cancer cell application.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Stromal cell-derived factor-1 (SDF-1), systematically referred to
as C-X-C motif chemokine 12 (CXCL12) is a small (8kDa) soluble
chemokine belonging to the family of a-chemokines, which are
characterised by a non-conservative amino acid separating the first
two cysteine residues (C-X-C motif) [1]. CXCL12 is one of the most
conserved chemokines known so far [2] showing very high
sequence similarities between different species, e.g. human andmurine mature CXCL12 show 99% sequence identity [3–6]. There
are 6 different splice isoforms of human CXCL12 (a, b, c, d, e, u)
[7] with CXCL12a being the most common splice variant in human
tissue [8] and therefore referred to as ‘‘CXCL12” in this article.
CXCL12 is constitutively expressed for homeostatic cell migra-
tion and proliferation guiding and respectively activating numer-
ous cells e.g. lymphocytes [9], dendritic cells [10] hematopoietic
stem cells [11], as well as endothelial cells [12] and endothelial
progenitor cells [13] via binding to the seven-span transmembrane
G protein-coupled receptor CXCR4. Activation takes place in a
proposed two-step two-site mechanism [14] mainly through
N-terminal amino acids. As more than 70% of tumour cells show
overexpression of CXCR4, the CXCR4/CXCL12 axis plays a pivotal
role in tumour pathogenesis with breast, lung, colon and prostate
cancer being some of many examples [15–23]. Tumour prolifera-
tion and survival are enhanced by paracrine signalling of tumour
associated stromal cells expressing CXCL12 whereas metastases
formation is caused by CXCL12 gradient formation in distant
organs attracting CXCR4-expression tumour cells [22]. Additionally
a second receptor for CXCL12, referred to as CXCR7 or atypical
chemokine receptor 3 (ACKR3), has been identified [24]. Apart
from the aforementioned profound role of CXCL12 in cancer its
involvement was also shown in several other pathologic conditions
for instance in rheumatoid arthritis [25,26], systemic lupus
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esis [32] or WHIM syndrome [33].
Adding further complexity to CXCL12 biology, glycosaminogly-
cans (GAGs), localised on the luminal side of vascular endothelial
cells, interact with CXCL12 to form a solid phase chemokine gradi-
ent for directed cell attraction. This process is important during
inflammation, but is also used by cancer cells for invasion and
metastases [34]. GAGs, i.e. heparin, heparan sulfate (HS), dermatan
sulfate, chondroitin sulfate, keratan sulfate, are linear, highly neg-
atively charged (sulfate and carboxylate groups) polysaccharides
comprising repeating disaccharide units that differ in the type of
disaccharide, linkage composition and N- and O-sulfation pattern
[35]. They are commonly linked to core proteins forming
proteoglycans such as syndecans and glypicans [36]. GAGs are
co-receptors for a variety of binding partners e.g. chemokines
which often possess an intrinsic selectivity for well-defined GAG
sequences [37,38]. The nature of the chemokine/GAG interaction
is mainly electrostatic and is unspecifically formed between posi-
tive protein amino acids and negatively charged GAG sulfate
groups. Selectivity/specificity is introduced via hydrophobic inter-
actions and hydrogen bonding with rather rare glycan sequences
which are tissue specific and dynamically regulated in pathologic
conditions like inflammation [39,40]. The BBXB consensus
sequence for GAG recognition, where B is a basic amino acid resi-
due and X a non-conserved amino acid [41], is found in Lys24,
His25 and Lys27 of CXCL12 but Lys1, Arg41 and Lys43 were
additionally reported to contribute to GAG binding [42,43].
Apart from the pivotal role in cell guidance, GAG binding to
CXCL12 is also involved in protecting CXCL12 against proteolytic
degradation [44].
Here we describe the engineering of dominant-negative
CXCL12a mutants which exhibit enhanced and specific GAG
binding combined with impaired GPCR signalling leading to GAG
silencing and thus to preventing tumour cell recruitment to
the murine liver after systemic application of the chemokine
mutant [45].
2. Materials and methods
If not stated otherwise all chemicals were purchased from
Sigma–Aldrich.
2.1. Protein design, expression and purification
For generating the mutants the gene sequence of mature
CXCL12a (1–68), Uni-Prot # P48061-2, was used (although con-
taining a leading methionine residue – due to bacterial expression
– the protein will be referred to as wtCXCL12a since the
N-terminal Met did not influence GAG nor GPCR binding). The
mutants were designed using the CellJammer discovery technol-
ogy which is based on structural analysis of the chemokine and
rational replacement of non-essential amino acids in the GAG-
binding sites by lysine or arginine residues by trying to conserve
the overall conformation [46,47]. Overlapping receptor- and GAG
binding amino acids, exemplified by Leu29, Val39 and Val49, and
the reported 2.4-fold decrease of affinity towards CXCR4 upon
mutating Val49 against Ala [48] led to the exchange of the respec-
tive amino acids with Arg or Lys to further impede the receptor
binding and to simultaneously increase GAG binding affinity by
enlarging adjacent GAG binding motifs, e.g. Lys24, His25, Lys27
[42,43,49]. In a last refinement we tried to increase the
C-terminal GAG binding site by mutating positions 60, 67 and 68
using different combinations of Lys and Arg. Before being cloned
and expressed in Escherichia coli each variant was tested in silico
to examine whether the mutations were energetically favourable
using the energy minimisation and molecular dynamics tools ofthe YASARA program (YASARA.com, data not shown). Synthetic
wtCXCL12a and mutant genes were codon optimised for expres-
sion in E. coli and cloned in the pJexpress411 expression vector
(DNA2.0, Inc.). Transformation in chemically competent E. coli
BL21 StarTM (DE3) (Invitrogen) was conducted in accordance to
the supplier’s manual. Protein expression and purification was
performed according to protocols published for other chemokine
mutants [50].
In total, 14 dominant-negative CXCL12 mutants were gener-
ated: CXCL12 (D8 L29K), CXCL12 (D8 E60K), CXCL12 (D8 L29K
V39K), CXCL12 (D7 L29K V39K), CXCL12 (D8 L29K V39R), CXCL12
(D8 L29R V39K), CXCL12 (D8 L29R V39R), CXCL12 (D7 L29R V39R),
CXCL12 (D8 L29K V39K N67K), CXCL12 (D8 L29K V39K E60K),
CXCL12 (D8 L29K V39K E60K N67K), CXCL12 (D8 L29K V39K
E60K N67K K68R), CXCL12 (D8 L29K V39K V49A), CXCL12 (D8
L29K V39K E60K K68R). Based on increased GAG-binding affinity,
GPC receptor knock-out, expression yield and protein stability
(data not shown), the two mutants CXCL12 (D8 L29K V39K) and
CXCL12 (D8 L29K V39K E60K N67K K68R) were studied in more
detail.
2.2. CXCR4 binding
Cell membrane homogenates of CXCR4-transfected CHO cells
were incubated with 10 pM [125I]wtCXCL12 at 22 C for 1 h in a
25 mM HEPES-NaOH, 5 mM MgCl2, 1 mM CaCl2, 0.1% NaN3,
0.5% BSA, pH 7.6, buffer. Incubation was either done with 10 pM
[125I]wtCXCL12 alone or together with different concentrations of
test samples. After incubation, samples were filtered through glass
fibre filters (GF/B; Packard) and rinsed several times with an ice-
cold 25 mMHEPES-NaOH, 5 mMMgCl2, 1 mM CaCl2, 500 mMNaCl,
0.5% BSA buffer using a 96-sample cell harvester (Unifilter;
Packard). Filters were dried and radioactivity readout by scintilla-
tion counting (Topcount; Packard) using a scintillation cocktail
(Microsint 0; Packard). Results were expressed as percent
inhibition of binding of the radioactively labelled wtCXCL12. The
resulting competition curve was used for calculation of the IC50
concentration i.e. the concentration causing half-maximal inhibi-
tion of [125I]wtCXCL12 binding.
2.3. Heparin displacement
25 lg of CXCL12 variants were loaded onto a HiTrap Heparin HP
1 mL column (GE Healthcare) and eluted with a gradient from
buffer A (PBS, pH 7.2) to 100% buffer B (PBS, 2 M NaCl, pH 7.2).
The NaCl concentration was calculated from the elution peak
maximum.
2.4. Surface plasmon resonance (SPR)
BiacoreTM measurements were conducted as described in a
recently published procedure [51]. Low molecular weight heparin
(Iduron) was biotinylated via reductive amination, which was also
specified in the aforementioned paper. C1 chips directly coated
with neutravidin, which showed lower background binding com-
pared to standard streptavidin chips, were used for immobilisation
of biotinylated heparin.
2.5. Breast cancer seeding model
All animal experiments were approved by local authorities.
MDA-MB-231, a human breast cancer cell line, was injected in
mice and cells metastasised to the lungs were re-isolated and
named hereafter LMD231 [52]. LMD231 cells were cultured in a
1:1 mixture of complete RPMI 1640 medium and complete mini-
mum essential medium at 37 C, 5% CO2. Female, 10 weeks old
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Fig. 1. Receptor binding study with increasing amounts of wtCXCL12, CXCL12 (D8
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1.2  105 LMD231 cells were injected into the tail vein of each
mouse. Just before injection cells were either mixed with CXCL12
(D8 L29K V39K) in doses of 0.1 mg/kg or 1 mg/kg or PBS for the
vehicle group (n = 7 each). The same two doses and PBS (for the
vehicle group) were daily administered to each group (without
LMD231 for all subsequent application) for a time period of 6 days.
Mice were sacrificed on day 28 and organs harvested. The liver was
fixed in formalin and later embedded in paraffin wax. 2 sections of
each liver were stained with cytokeratin markers for human
epithelial cells (breast cancer). Liver sections were then assessed
per high power field (HPF; 8 fields assessed in each section) and
the amount of metastases determined. Total number of metastases
in each section was then counted and average metastases per
square mm were calculated. Statistical significance was assessed
using GraphPad Prism (GraphPad Software) and P value threshold
of <0.05.L29K V39K) and CXCL12 (D8 L29K V39K E60K N67K K68R), competing with [125I]-
wtCXCL12 for CXCR4.
Table 1
NaCl/heparin displacement and Kd values of wtCXCL12 and CXCL12 mutants (Kd
values are shown together with the standard error resulting from non-linear fitting of
the raw data to a model of bi-molecular interaction).
CXCL12 variant Hep displ. (NaCl
conc.) (M)
ITC HS
(Kd) (nM)
SPR heparin
(Kd) (nM)
wtCXCL12 1.06 257 ± 30 366 ± 67
CXCL12 (D8 L29K V39K) 1.39 117 ± 26 65 ± 20
CXCL12 (D8 L29K V39K
E60K N67K K68R)
1.38 81 ± 12 21 ± 23. Results and discussion
We have recently applied our decoy engineering approach to
three pro-inflammatory chemokines [46]. Here we have for the first
time engineered a homeostatic chemokine, CXCL12a, in order to
silence its target tissue/organ and to prevent penetration by
attracted cells. Our aim was to significantly increase the affinity
for glycosaminoglycans (GAGs) of CXCL12a as well as to knock-
out its GPCR binding domain. We have chosen mature CXCL12a
(aa 1–68), as this is themost common splice variant in humans [7,8].
Jurkat cells are typically used in chemotaxis assays with CXCL12
[53,54]. In our hands, 100 nM wtCXCL12 gave the highest
chemotactic response, as expressed in a chemotactic index of
184, which was therefore taken as point of reference for calculating
the reduction of the signal in percent detected for the mutants at
the same concentration. For all CXCL12 decoy proteins tested, the
reduction in chemotaxis compared to the wild-type was well over
>90%. Only at artificially high protein concentrations (1000 nM and
10000 nM), the mutant chemokines exhibited very weak chemo-
taxis (data not shown). Deletion of the 8 leading amino acids is
thus sufficient for knocking out chemotaxis. In order to check
whether despite lack of chemotaxis the mutant chemokines are
still able to bind to CXCR4, receptor displacement studies were
performed.
Binding of CXCL12 to CXCR4 occurs in two steps: the first one is
responsible for the initial contact and the second one finally acti-
vates the receptor through the CXCL12N-terminus [14,55]. By
deleting the first eight amino acids, we aimed at inhibiting the
second step as well as additionally reducing the overall affinity
to CXCR4. In most of our CXCL12 variants there were further
mutations introduced at positions mostly important for the first
receptor binding step, which partly overlap with the GAG binding
site at positions 29 and 39. Therefore, two mutants were chosen for
the competition assay: CXCL12 (D8 L29K V39K) as it seemed to
represent the minimal change required to combine GPC knock-
out and GAG-binding affinity increase, and CXCL12 (D8 L29K
V39K E60K N67K K68R) as it contained on top of the minimal
dominant-negative engineering requirements three more muta-
tions in the 60’s region of the C-terminal GAG-binding site. The
amount of radioactively labelled wtCXCL12 bound to the receptor
was determined in the presence of increasing concentrations of
cold wtCXCL12, CXCL12 (D8 L29K V39K) and CXCL12 (D8 L29K
V39K E60K N67K K68R), respectively. The IC50 value for wtCXCL12
was found to be 26 pM (see Fig. 1). For the two mutant proteins it
was not possible to calculate respective values since they failed to
reduce wtCXCL12 binding to CXCR4 by 50% (see Fig. 1). It can
therefore be concluded that the mutations introduced into CXCL12not only knocked-out CXCR4-signalling but also almost completely
disabled receptor binding itself.
In a next step we looked for the heparin binding strength which
relates only to ion pairing. For this purpose, heparin chromatogra-
phy combined with limiting NaCl elution was applied, i.e. the
higher the ion-pair based binding strength the more sodium chlo-
ride is necessary to disrupt this binding and to elute the protein off
the heparin column (see Table 1). By this means, wtCXCL12 eluted
with 1.06 M sodium chloride, whereas CXCL12 (D8 L29K V39K)
and CXCL12 (D8 L29K V39K E60K N67K K68R) both eluted with
similar NaCl concentrations namely with 1.39 M NaCl and 1.38 M
NaCl, respectively. These results show clearly that introducing
basic amino acids in the 60’s region of the chemokine’s
C-terminus did not lead to a further improvement of ion pair-
based affinity towards heparin.
In order not to focus on ion pairing but to also take into account
hydrogen bonding and hydrophobic interactions between chemo-
kine (mutants) and the heparin ligand, surface plasmon resonance
was applied (see Fig. 2). For low molecular weight heparin a Kd
value of 366 nM was measured with wtCXCL12 (see Table 1). The
mutants CXCL12 (D8 L29K V39K) and CXCL12 (D8 L29K V39K
E60K N67K K68R) showed an increase in heparin binding affinity
of 5.6-fold and 17.4-fold, respectively. Since ion pairing between
chemokine mutants and heparin was apparently saturated by
introducing the L29K V39K mutations, the affinity difference
between the two CXCL12 mutants found here is interpreted to be
due to additional hydrogen bonds and/or hydrophobic interactions
in the fivefold mutant compared to the twofold mutant. Since
hydrogen bonds and hydrophobic interactions are responsible for
the specificity of the protein–GAG interaction it must be assumed
that exchanging residues in the 60’s region of CXCL12 by basic
amino acids, though leading to a further improved GAG-binding
affinity compared to modifying only the 29 and 39 site, will
strongly impact on the ligand selectivity of the chemokine mutant.
Fig. 2. Surface plasmon resonance data of wtCXCL12, compared with the mutants
CXCL12 (D8 L29K V39K) and CXCL12 (D8 L29K V39K E60K N67K K68R), binding to
low molecular weight heparin. Extracted Kd values are shown in Table 1 (for
experimental details see Section 2).
Fig. 3. Isothermal titration calorimetry data of wtCXCL12, compared with the
mutants CXCL12 (D8 L29K V39K) and CXCL12 (D8 L29K V39K E60K N67K K68R),
binding to unfractionated heparan sulfate. Extracted Kd values are shown in Table 1
(for experimental details see Section 2).
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CXCL12 mutants towards heparan sulfate (HS), which is the most
like natural GAG ligand of this chemokine. Isothermal titration
calorimetry (ITC) was used to quantify the energy/heat that was
released from or absorbed by the binding process of CXCL12
mutants and GAGs giving the dissociation constants (Kd values)
of the interaction shown in Table 1. For wtCXCL12, a Kd value of
257 nM was detected, an affinity which the mutants CXCL12 (D8
L29K V39K) and CXCL12 (D8 L29K V39K E60K N67K K68R) super-
seded by a factor of 2.2 and 3.2, respectively (see Fig. 3). Unfrac-
tionated HS, which was used here, differs from low molecular
weight heparin not only by size but also by the arrangement of sul-
fated regions: heparin seems to be homogeneously sulfated
whereas HS exhibits large unsulfated regions. Due to the generally
lower availability of sulfated regions in HS for chemokine bindingcompared to heparin, the engineered improvement in GAG-
binding affinity is less pronounced for the two mutants compared
to the wild type in the case of the HS ligand. However, the
significant difference in affinity between the two mutants again
refers to more hydrogen bonds and hydrophobic interactions
which CXCL12 (D8 L29K V39K E60K N67K K68R) can establish
with the HS ligand compared to CXCL12 (D8 L29K V39K).
Therefore, in order to avoid unspecific GAG ligand interactions,
only the CXCL12 (D8 L29K V39K) mutant was investigated
in vivo for its GAG-silencing potential.
CXCL12 plays a major role in tumour angiogenesis, metastases
and breast cancer in particular and therefore a recently established
breast cancer seeding model [52] was chosen to further examine
Fig. 4. Effect of six days administration of 1 mg/kg CXCL12 (D8 L29K V39K) on
cancer cell metastases. Number of liver metastases per HPF.
M. Gschwandtner et al. / FEBS Letters 589 (2015) 2819–2824 2823the CXCL12 (D8 L29K V39K) variant that emerged from the previ-
ous characterisations. Human breast cancer cells (MDA-MB-231)
carrying CXCR4 receptors [56] were used for inoculation of mice
and were re-isolated from lung metastases of these mice as
LMD231 cells. LMD231 cells were shown by FACS analysis to
express very high levels of CXCR4 compared to parental cells
[52]. LMD231 cells were administered i.v. in SCID mice which were
then treated with daily injections of either PBS for the vehicle
group or 0.1 mg/kg and 1 mg/kg CXCL12 (D8 L29K V39K), respec-
tively. Animals treated with 0.1 mg/kg CXCL12 (D8 L29K V39K)
were within the range of the vehicle-treated group (data not
shown). 1 mg/kg CXCL12 (D8 L29K V39K), however, significantly
reduced the amount of liver metastases in this model (see Fig. 4).
This shows that GAG-silencing using a CXCL12 decoy protein sig-
nificantly inhibits cancer cell migration and therefore metastases
formation.
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